RxDoctor Payments Data

Kenneth Mandell, MD

Internal Medicine · Delray Beach, FLNPI 1245257724

Payments from drug & device makers

$3,591in general payments, 2019–2025

Across 135 payments — averaging $26.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$511
  • E.r. Squibb & Sons, L.L.C.$470
  • Novartis$389
  • Boehringer Ingelheim$344
  • Amgen$326
  • Abbott$255
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,591100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,591 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$584,906
Medicare patients
2,142
Services billed
4,902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban299$378,568
XareltoRivaroxaban112$106,451
EntrestoSacubitril/Valsartan40$68,307
MultaqDronedarone Hcl22$52,042
JardianceEmpagliflozin32$49,428
Repatha SureclickEvolocumab39$26,637
Repatha PushtronexEvolocumab20$14,551
FarxigaDapagliflozin Propanediol16$9,382
Metoprolol Succinate334$5,992
NexlizetBempedoic Acid/Ezetimibe14$5,553
Rosuvastatin Calcium205$3,306
Valsartan111$3,031
Ezetimibe113$2,626
Midodrine Hcl25$2,557
Atorvastatin Calcium252$2,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$511$378,568299 claims
Johnson & JohnsonXarelto$32$106,451112 claims
NovartisEntresto$389$68,30740 claims
Sanofi-aventis U.S. LLCMultaq$218$52,04222 claims
Boehringer IngelheimJardiance$344$49,42832 claims
AstraZenecaFarxiga$119$9,38216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →